Needham & Company downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Hold after the FDA issued a major set back ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Deutsche Bank Cuts Sarepta Therapeutic (SRPT) to Hold, PT $17November 12, 2013 3:54 PM FBR Capital Slashes Sarepta (SRPT) Price Target, But Remains 49% Above Current LevelsNovember 12, 2013 2:45 PM Sarepta (SRPT) Target Cut to $45 at Wedbush, Analyst Expects Larger Eteplirsen TrialNovember 12, 2013 2:22 PM Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche BankNovember 12, 2013 9:25 AM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightNovember 12, 2013 8:11 AM FDA Considers Sarepta's (SRPT) NDA for Eteplirsen 'Premature'November 12, 2013 7:05 AM